Verification & Public Laboratory Reports
Pexrit Labs publishes available third-party analytical reports so researchers can review the testing that is actually documented.
Current Report Summary
| Product / tested strength | Laboratory ID | Lot on report | Chromatographic purity | Measured quantity |
|---|---|---|---|---|
| Tirzepatide 10MG | V260601-26 001 | PX-TIRZ-250526-01 | >99.80% + 0.18% | 10.70 mg |
| Retatrutide 10MG | V260601-26 002 | PX-RETA-250526-01 | 98.86% + 0.18% | 11.74 mg |
| Semaglutide 10MG | V260601-26 003 | PX-SEMA-250526-01 | 99.11% + 0.18% | 10.30 mg |
| BPC-157 10MG | V260601-26 004 | PX-BPC157-250526-01 | >99.80% + 0.18% | 11.09 mg |
| TB-500 10MG | V260601-26 005 | PX-TB500-250526-01 | >99.80% + 0.18% | 10.95 mg |
| Ipamorelin 10MG | V260601-26 006 | PX-IPA-250526-01 | 97.55% + 0.18% | 10.13 mg |
| Tesamorelin 10MG | V260601-26 007 | PX-TESA-250526-01 | 99.05% + 0.18% | 10.74 mg |
All seven reports above were reported June 8, 2026. Values are transcribed from the linked Vanguard Laboratory reports.
Current Inventory Lot Matching
Pexrit Labs confirms that the current vials are labeled with the same lot numbers shown in the corresponding public laboratory reports above. This is a Pexrit Labs inventory and labeling confirmation; the laboratory reports themselves still establish results only for the tested samples described in those reports.
Public Reports
- Tirzepatide 10MG: View report (PDF)
- Retatrutide 10MG: View report (PDF)
- Semaglutide 10MG: View report (PDF)
- BPC-157 10MG: View report (PDF)
- TB-500 10MG: View report (PDF)
- Ipamorelin 10MG: View report (PDF)
- Tesamorelin 10MG: View report (PDF)
Testing Scope
The current reports document chromatographic purity and quantity using HPLC-UV/VIS. Pexrit Labs does not represent that identity, sterility, endotoxin, microbiological, or other testing was performed unless that analysis is specifically shown on the applicable report.
What the Reports Do—and Do Not—Establish
Each Vanguard Laboratory report states that the result relates only to the portion of the sample tested. The reports also state that the laboratory did not observe or participate in sample selection and cannot confirm the authenticity of the sample or its representativeness of the associated lot or batch.
Strength-Specific Documentation
The currently published Tirzepatide report is for the 10MG tested sample. Separate public reports for the 30MG and 60MG strengths are not currently published.
The currently published Retatrutide report is for the 10MG tested sample. Separate public reports for the 20MG and 48MG strengths are not currently published.
Questions
For questions about current product documentation or lot matching, contact info@pexritlabs.com.
Research Use Only
All Pexrit Labs products are intended strictly for laboratory research and in vitro testing only. They are not intended for human or animal use.